证券代码：301096 证券简称：百诚医药 公告编号：2023-014 杭州百诚医药科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 （问题征集专题页面二维码） 特此公告。 杭州百诚医药科技股份有限公司董事会 杭州百诚医药科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 29 日在 巨潮资讯网（http://www.cninfo.com.cn）披露了《2022 年年度报告》及其摘要。 为了方便投资者了解公司 2022 年度业绩的相关情况，公司定于 2023 年 4 月 12 日（星期三）15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说明会 将采用网络远程的方式举行，投资者可登录全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有:公司董事长兼总经理楼金芳女士，董事、副总经理兼董 事会秘书刘一凡女士，财务总监颜栋波先生，独立董事任成先生，保荐代表人余波先 生。 为充分尊重投资者、提升交流的针对性 ...

Company Overview - Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. is a comprehensive pharmaceutical R&D enterprise focused on technology development, covering generic drugs and the consistency evaluation of their quality and efficacy [1]. - The company provides integrated services across the pharmaceutical industry chain, including pharmaceutical research, clinical trials, custom production, and registration applications, serving over 300 clients with more than 400 projects [1]. CDMO Development - The CDMO production base, Seimer Pharmaceutical, has established a full-process service platform, covering an area of over 180 acres and a GMP-standard facility of 101,000 square meters [2]. - In the first half of 2022, the company registered 58 projects, receiving approvals for 13, including the first nationwide approval for an injectable form of Fludarabine Phosphate [2]. Financial Performance - In the first half of 2022, the company achieved a revenue of 69.17 million yuan, an increase of 85.33% year-on-year, with a gross profit margin of 75.86% [3]. - The company has 250 ongoing independent R&D projects, with 137 in the small-scale testing phase and 36 in the pilot scale-up phase [2]. Workforce and Talent Development - As of June 30, 2022, the company employed 1,185 staff, with 874 in technical R&D roles, representing 73.76% of the workforce, and 80.05% of technical staff holding a bachelor's degree or higher [3]. - The company plans to expand its workforce in line with business growth, particularly in the new investment project in Hangzhou [3]. Market Outlook - The demand for generic drug development is expected to remain strong due to factors such as an aging population, urbanization, and increased disposable income in China [3]. - The implementation of the MAH system is anticipated to further stimulate pharmaceutical R&D enthusiasm, ensuring a sustainable demand for generic drugs [3]. Recovery Post-Pandemic - Following the pandemic, the company has seen a gradual recovery in project development and business expansion, with R&D progress steadily improving after the Chinese New Year [3].

Group 1: Company Overview - Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. is a comprehensive pharmaceutical R&D enterprise focused on technology development, providing integrated R&D services including CRO and CDMO [2][3]. - The company has served over 300 clients, delivering more than 400 projects in pharmaceutical research and clinical trials [3]. Group 2: CDMO Development - The CDMO production base, Saime Pharmaceutical, covers over 180 acres with a GMP-standard facility of 101,000 square meters, having obtained a drug production license in March 2021 [3]. - In the first half of 2022, the company registered 58 projects, receiving approvals for 13, including the first nationwide approval for an injectable drug [3][4]. Group 3: Financial Performance - The self-developed technology transfer segment generated revenue of 69.17 million CNY in the first half of 2022, marking an 85.33% increase year-on-year, with a gross margin of 75.86% [4]. - The revenue from profit-sharing projects reached 30.95 million CNY, with a gross margin of 99.32%, reflecting a 145.18% increase compared to the previous year [4]. Group 4: Future Plans and Recruitment - The company plans to complete a fundraising project in Linping District by mid-2023, covering an area of 30,785 square meters with a building area of 97,700 square meters [4]. - As of the report date, the company has over 250 ongoing self-developed projects and has added 420 employees, increasing its R&D personnel to 874 [4].

证券代码：301096 证券简称：百诚医药 杭州百诚医药科技股份有限公司 投资者关系活动记录表 编号：2022-029 | --- | --- | --- | --- | --- | --- | --- | |--------------|-------------------------------|------------------------------------------------------|-------|-------|-----------------------------------------------------------------------------------------------------------|----------| | 投资者关系活 | 特定对象调研 | 分析师会议 | | | | | | 动类别 | | □媒体采访 □业绩说明会 | | | | | | | □新闻发布会 | □路演活动 | | | | | | | □现场参观 | | | | | | | | 其他 （电话） | | | | | | | 参与单位名称 | | 长城基金：龙宇飞；信达医 ...

Group 1: Company Overview - The company is a comprehensive pharmaceutical technology R&D enterprise focused on pharmaceutical research, providing drug development services and technology transfer [1] - It adopts a dual development strategy of "entrusted R&D services + R&D technology results transformation" [1] - The company has established strong core competitive advantages in pharmaceutical research and bioequivalence testing services [1] Group 2: R&D Platforms and Collaborations - The company has created various R&D platforms, including innovative drug R&D, generic drug evaluation, and bioequivalence (BE) studies, enhancing its core technical advantages [3] - Strategic partnerships with hospitals like Wenzhou Medical University Second Affiliated Hospital and Dongyang Hengdian Hospital facilitate BE clinical trials at lower costs compared to similar hospitals in Hangzhou [3] Group 3: Impact of Centralized Procurement - Centralized procurement has become normalized, with a procurement cycle of 1-3 years for winning drugs, allowing new products to participate in national procurement [3] - The number of participating manufacturers in centralized procurement is increasing, with the maximum number of winning companies rising from 1 to 10, which helps ensure drug supply [3] Group 4: Revenue Sources and Project Rights - The company's revenue primarily comes from entrusted R&D services and technology transfer, with projects categorized into those with and without sales rights sharing [4] - In the first half of 2021, the company earned a revenue share of 12.62 million yuan (including tax) from a collaboration with Huayuan Pharmaceutical for Valsartan Amlodipine tablets [4]

Company Overview - Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. focuses on technology development as a core aspect of its comprehensive pharmaceutical R&D services, including CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services [2][3]. - The company has provided integrated R&D services to over 300 clients, completing more than 400 projects in pharmaceutical research and clinical trials [3]. Business Operations - The main business areas include generic drug development, quality and efficacy consistency evaluation, custom R&D production services, and innovative drug development [3]. - As of December 31, 2021, the company operated in a laboratory and office space of 18,000 m² with 765 employees and advanced equipment [3]. Infrastructure Development - The company is constructing a new headquarters and R&D center in Linping District, Hangzhou, covering 46.18 acres, expected to be operational by mid-2023, increasing the laboratory and office space to 73,900 m² [3][5]. - The subsidiary, Zhejiang Saime, has a custom R&D production base covering over 180 acres, with a construction area of 137,100 m² and an investment of 437.804 million yuan as of December 31, 2021 [3]. Financial Performance - In the second half of 2021, Zhejiang Saime's CDMO business generated revenue of 9.4014 million yuan, supporting 57 commissioned R&D projects [3]. - The company registered 62 projects during the reporting period, receiving approvals for 23, including two projects as the first in the nation [3]. Future Projections - The CDMO production capacity is projected to reach 156.57 tons of raw materials and 3 billion oral solid dosage forms annually after the completion of the second phase of construction [4]. - The company anticipates continued growth in the pharmaceutical market driven by an aging population, urbanization, and increased disposable income, with a strong focus on generic drugs [4]. Talent Acquisition and Development - The company is actively recruiting specialized personnel in pharmacy and medicine to meet the increasing project demands, supported by a recent stock incentive plan to stabilize and attract talent [5].

证券代码：301096 证券简称：百诚医药 杭州百诚医药科技股份有限公司 投资者关系活动记录表 编号：2022-025 | --- | --- | --- | --- | --- | --- | |---------------|-----------------|----------------------------------------------------|-------|-------|-------| | | | | | | | | 投资者 关系活 | 特定对象调研 | 分析师会议 | | | | | 动类别 | | □媒体采访 □业绩说明会 | | | | | | | □新闻发布会 □路演活动 | | | | | | 现场参观 | | | | | | | 其他 （电话） | | | | | | 参与单 位名称 | | 国元证券：马云涛；华西证券：徐顺利 | | | | | 及人员姓名 | | 鹏扬基金伍智勇、崔洁铭；招商信诺资产：詹孝颖； | | | | | | | 勤远投资：魏雅雯；睿郡资产：魏志华； | | | | | | | 凯昇资本：叶挺；金友创智资产：李宁；杭银理财：王哲 | | ...

Revenue and Profit Growth - Revenue for Q3 2022 reached ¥175,075,260.37, an increase of 116.03% compared to the same period last year[6] - Net profit attributable to shareholders was ¥60,200,473.64, reflecting a growth of 155.42% year-over-year[6] - The net profit excluding non-recurring items was ¥59,114,873.33, up 153.75% from the previous year[6] - Basic earnings per share for the quarter was ¥0.56, a 93.10% increase compared to the same period last year[6] - The company's operating revenue increased to ¥222,306,353.54, representing a growth of 89.26% compared to the same period last year, driven by a strengthened business model of "technology transformation + entrusted development + profit sharing"[14] - Total operating revenue for the third quarter of 2022 reached ¥420,743,410.29, a significant increase of 89.5% compared to ¥222,306,353.54 in the same period last year[31] - The company reported a total profit of 154,492,098.56 CNY for the quarter, compared to 70,413,983.03 CNY in the previous year, indicating an increase of about 119.8%[37] Assets and Liabilities - Total assets as of September 30, 2022, were ¥2,722,802,500.36, a decrease of 6.91% from the end of the previous year[6] - The total liabilities decreased to ¥305,608,047.34 from ¥607,099,838.11, a reduction of 49.7%[27] - Estimated liabilities rose by 46.38% to ¥125,635,824.68, as the company recognized liabilities corresponding to the progress of entrusted and self-developed projects[14] - The equity attributable to shareholders of the parent company increased to ¥2,417,361,324.83 from ¥2,317,911,097.31, an increase of 4.3%[30] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was ¥157,648,719.74, an increase of 154.33% year-over-year[6] - The net cash flow from operating activities reached ¥157,648,719.74, a significant increase of 154.33% year-on-year, attributed to higher operating income and improved accounts receivable collection[17] - The company experienced a 240.22% increase in cash flow from investing activities, resulting in a net outflow of ¥467,493,195.28, driven by ongoing project investments[17] - Cash outflows from investing activities amounted to 471,497,885.54 CNY, compared to 228,684,414.89 CNY in the previous year, leading to a net cash flow from investing activities of -467,493,195.28 CNY[40] Expenses and Financial Performance - Research and development expenses surged by 167.37% to ¥42,489,710.84, reflecting the company's ongoing investment in innovative and generic drug development[14] - The company's income tax expense increased by 56.02% to ¥9,328,893.49, reflecting higher profits during the reporting period[17] - The financial expenses increased dramatically by 2912.60%, amounting to ¥1,177,436.68, primarily due to increased interest on raised funds[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,547, indicating a stable shareholder base[18] Inventory and Contract Assets - Inventory increased by 142.23% to ¥55,353,854.97 due to increased production activities[11] - Contract assets grew by 109.58% to ¥98,910,980.94, driven by rapid revenue growth[11] - The company reported a significant increase in prepayments, which rose by 100.91% to ¥26,603,377.79, attributed to increased clinical business activities[11] Cash and Cash Equivalents - The company reported cash outflows from financing activities amounted to 361,282,406.46 CNY, while cash inflows were recorded at 126,747,271.43 CNY, resulting in a net cash flow from financing activities of -361,282,406.46 CNY[40] - The ending cash and cash equivalents balance was 1,337,874,628.84 CNY, down from 157,569,933.40 CNY at the end of the previous year[40] - The company's cash and cash equivalents decreased to ¥1,341,573,128.84 from ¥2,013,001,510.85, a decline of 33.3%[24]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[2] - The net profit attributable to shareholders was RMB 100 million, with a growth rate of 15% compared to the same period last year[2] - Future guidance indicates expected revenue growth of 25% for the full year 2022, projecting total revenue of RMB 1.2 billion[2] - The company's revenue for the reporting period reached CNY 245,668,149.92, representing a 73.91% increase compared to CNY 141,262,964.39 in the same period last year[36] - Net profit attributable to shareholders was CNY 85,021,258.82, an increase of 107.62% from CNY 40,949,487.61 year-on-year[36] - The net cash flow from operating activities was CNY 105,093,103.55, a significant increase of 295.01% compared to CNY 26,604,864.69 last year[36] - Basic earnings per share increased to CNY 0.79, reflecting a growth of 58.00% from CNY 0.50 in the previous year[36] - The company reported a significant increase in financial expenses, with a change of -4,636.10% to -¥22,452,303.28, mainly due to increased interest on raised funds[113] - The company experienced a 44.74% increase in income tax expenses to ¥4,734,668.68, correlating with the rise in profit[113] Market Expansion and Product Development - User data showed an increase in active users by 30%, reaching a total of 1 million active users by the end of June 2022[2] - The company plans to launch two new products in Q4 2022, aiming to capture a 10% market share in the new segments[2] - The company is expanding its market presence in Southeast Asia, targeting a 15% increase in sales from this region by the end of 2023[2] - The company continues to focus on the development of new drugs and technologies, enhancing its market position and expanding its product offerings[33] - The company is exploring acquisition opportunities to enhance its product portfolio and market reach, with a focus on strategic partnerships[2] - The company is focusing on market expansion strategies to enhance its competitive position in the industry[176] Research and Development - Research and development expenses increased by 40%, totaling RMB 50 million, to support new product development and innovation[2] - The company has retained sales rights sharing agreements with some clients, allowing for continuous revenue generation from drug sales throughout the product lifecycle[56] - The company is currently developing 6 innovative drug projects targeting various pathways, with one project (BIOS-0618) having received clinical approval and entering Phase I trials[59] - The company has established a complete CDMO service platform to enhance drug development efficiency and reduce costs, facilitating the transition from laboratory research to commercial production[57] - The company has over 250 ongoing independent R&D projects with high customer acceptance, which is expected to drive future revenue growth[99] - The company is focusing on six innovative drug projects, all classified as Category 1 new drugs, targeting areas such as neuropathic pain, tumors, and non-alcoholic fatty liver disease, indicating a broad market potential[99] - The company has a strong R&D team with 874 technical R&D personnel, accounting for 73.76% of total employees, and 80.05% of these personnel hold a bachelor's degree or higher[109] - The company is actively investing in R&D, with discussions on the planning and investment in the Semaglutide project and the conversion of R&D achievements into commercial results[166] Risk Management - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[5] - The company faces risks related to drug development failures and long development cycles, which may impact future business performance[151][155] - The company plans to enhance its R&D team and optimize drug development processes to mitigate risks associated with drug development failures[154] - The company is closely monitoring regulatory policies in the pharmaceutical industry to ensure compliance and mitigate risks[159] Environmental Management - The company has implemented various measures to control pollution, including optimizing production processes to reduce waste gas emissions and enhance solvent recovery efficiency[196] - The company has established a comprehensive wastewater treatment system, ensuring that wastewater meets discharge standards through various pre-treatment methods[197] - The company’s environmental management includes regular monitoring and compliance with national pollution discharge standards[193] - The company has adopted a closed production system to minimize unorganized waste gas emissions during manufacturing processes[196] - The company has established a solid waste management ledger and improved the hazardous waste management system within the plant[200] Employee Management and Incentives - The company has implemented stock incentive plans for 197 executives and core employees in June 2022, resulting in significant share-based payment expenses[160] - The company plans to implement an equity incentive plan aimed at enhancing employee motivation and aligning interests with shareholders[175] - The company has a total of 1,130,653 shares allocated to senior management and core employees through a strategic placement plan[187] - The company is focusing on optimizing its human resource management system to enhance employee value and overall profitability[162] Financial Strategy and Investments - The company has a total of CNY 36,387 million in excess raised funds, which will be used to permanently supplement working capital[136] - The company has invested CNY 100,452,602.68 in the Jinxi Industrialization Project Phase II, with a cumulative investment of CNY 112,243,862.49[127] - The company utilized CNY 16,558.14 million of the raised funds during the reporting period, with a cumulative investment of the same amount[131] - The company has not reported any significant changes in the measurement attributes of its main assets during the reporting period[126]